VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - June 12, 2006) - WEX Pharmaceuticals Inc. (“WEX” or the “Company”) (TSX:WXI) is pleased to announce that it has received approval for its IND (Investigational New Drug) application with the US FDA (Food and Drug Administration) to initiate a clinical trial of TectinTM. This represents a significant achievement since for the first time, WEX will perform a trial under a US-IND number, and this will grant access to a major patient population base for future TTX development.
